Targeting argininosuccinate synthetase-deficient advanced solid tumors in a phase I trial of ADI-PEG20 plus cisplatin

Authors :: Funda Meric-Bernstam
Naiyi Shi
Siqing Fu
Eevy Nguyen
John S. Bomalaski
Sarina Anne Piha-Paul
Patrick Hwu
Apostolia Maria Tsimberidou
Jennifer J. Wheler
Sapna Pradyuman Patel
David S. Hong
Ralph Zinner
Vivek Subbiah
Filip Janku
Gerald S. Falchook
Source :: Journal of Clinical Oncology. 32:2563-2563
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 2563 Background: Besides its selective activity to induce autophagy and caspase-independent apoptosis in argininosuccinate synthetase (ASS)-deficient cancer cells, ADI-PEG20 (pegylated arginine dei...

Subjects :: Cisplatin
Cancer Research
Arginine
biology
business.industry
Argininosuccinate synthase
Autophagy
Oncology
Apoptosis
Cancer cell
biology.protein
Cancer research
Medicine
business
medicine.drug

Tools